Table 7.70Adverse events in knee OA

Knee
Adverse eventsReferenceInterventionAssessment timeOutcome/effect size
HA Artz
Number of AEs probably/possibly related to treatment1 MA (Bellamy et al. 2006b) 2 RCTs, N=432HA Artz vs placebo5–13 weeks post-injectionRR 1.59, 95% CI 1.12 to 2.26, p=0.009
Favours placebo
Number of patients reporting AEs1 MA (Bellamy et al. 2006b) 1 RCT, N=156HA Artz vs placebo45–52 weeks post-injectionNS
HA BioHy
Number of AEs for injection site pain1 MA (Bellamy et al. 2006b) 1 RCT, N=49HA BioHy vs placeboNot mentionedNS
HA Durolane
Number of patients affected by device-related AEs; number of patients with AEs related to injection only; number of patients with non-serious treatment-related AEs; number of patients with non-serious AEs1 MA (Bellamy et al. 2006b) 1 RCT, N=347HA Durolane vs placeboNot mentionedNS
HA Hyalgan
Number of patients with adverse reaction but study drug continued1 MA (Bellamy et al. 2006b) 6 RCTs, N=666Hyalgan vs placeboNot mentionedRR 1.42, 95% CI 1.10 to 1.84, p=0.007
Favours placebo
Number of patients with local adverse reaction and study drug discontinued1 MA (Bellamy et al. 2006b) 4 RCTs, N=941Hyalgan vs placebo5–13 weeks post-injectionRR 3.34, 95% CI 1.31 to 8.56, p=0.01
Favours placebo
Number of patients reporting AEs; number of patients with serious or severe AEs and post-injection; number of knee joints with local adverse reaction; number of patients with injection site pain or painful intra-articular injection1 MA (Bellamy et al. 2006b)Hyalgan vs placebo14–26 weeks and 45–52 weeks post-injectionNS
HA Hylan G-F20
Number of patients not requiring additional treatment for study knee1 MA (Bellamy et al. 2006b) 1 RCT, N=152Hylan G-F20 vs placebo45–52 weeks post-injectionNS
Number of clinical failures1 MA (Bellamy et al. 2006b) 14–26 weeks: 1 RCT, N=152
45–52 weeks: 1 RCT, N=118
Hylan G-F20 vs placebo14–26 weeks and 45–52 weeks post-injection5–13 weeks: WMDNS
Number of patients with local reaction1 MA (Bellamy et al. 2006b) 6 RCTs, N=469Hylan G-F20 vs placeboNot mentionedNS
Number of patients with local adverse reactions but study drug continued1 MA (Bellamy et al. 2006b) 1 RCT, N=30Hylan G-F20 vs placeboNot mentionedNS
HA Suvenyl
Patient assessment of treatment efficacy (number of patients rating very good or good vs moderate, bad or very bad; number of patients reporting knee pain during or after intra-articular injection1 MA (Bellamy et al. 2006B)HA Suvenyl vs placeboNot mentionedNS
HA Orthovisc
Number of patients with treatment-related AEs; number of patients with local skin rash or musculoskeletal AEs1 MA (Bellamy et al. 2006b)HA Orthovisc vs placeboNot mentionedNS
HA Replasyn
Number of patients with local adverse reaction but study drug continued1 MA (Bellamy et al. 2006b) 1 RCT, N=39HA Replasyn vs placeboNot mentionedNS

From: 7, Pharmacological management of osteoarthritis

Cover of Osteoarthritis
Osteoarthritis: National Clinical Guideline for Care and Management in Adults.
NICE Clinical Guidelines, No. 59.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.